Immune OTC Stock Buy Hold or Sell Recommendation

IMUN -  USA Stock  

USD 2.30  0.60  20.69%

Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Immune Therapeutics is 'Strong Sell'. Macroaxis provides Immune Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding IMUN positions. The advice algorithm takes into account all of Immune Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.

Immune Advice 

 
Refresh
The advice is provided from Immune Therapeutics' buy-and-hold perspective. Please see Immune Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. We conduct extensive research on individual companies such as Immune and provide practical buy, sell, or hold advice based on selected investing horizon and risk tolerance towards Immune Therapeutics.

Execute Immune Therapeutics Buy or Sell Advice

The Immune recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Immune Therapeutics. Macroaxis does not own or have any residual interests in Immune Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Immune Therapeutics' advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Immune TherapeuticsBuy Immune Therapeutics
Strong Sell

Volatility

Extremely DangerousDetails

Hype Condition

Over hypedDetails

Current Valuation

OvervaluedDetails

Odds of Distress

Close to AverageDetails

Economic Sensitivity

Almost mirrors the marketDetails

Analyst Consensus

Not AvailableDetails

Reporting Quality (M-Score)

UnavailableDetails
For the selected time horizon Immune Therapeutics has a Mean Deviation of 6.33, Semi Deviation of 8.12, Standard Deviation of 12.11, Variance of 146.6, Downside Variance of 143.43 and Semi Variance of 65.89
We provide advice to complement the regular expert consensus on Immune Therapeutics. Our dynamic recommendation engine utilizes a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Immune Therapeutics is not overpriced, please check out all Immune Therapeutics fundamentals, including its book value per share, and the relationship between the net income and market capitalization . Please also validate Immune Therapeutics price to sales to confirm your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.

Immune Therapeutics Trading Alerts and Improvement Suggestions

Immune Therapeutics has very high historical volatility over the last 90 days
Immune Therapeutics has high likelihood to experience some financial distress in the next 2 years
Immune Therapeutics currently holds about 11.66 K in cash with (191.5 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02.
Roughly 17.0% of the company shares are held by company insiders
Latest headline from www.kulr8.com: MiNK Therapeutics Announces Closing of Initial Public Offering - KULR-TV

Immune Therapeutics Returns Distribution Density

The distribution of Immune Therapeutics' historical returns is an attempt to chart the future uncertainty of Immune Therapeutics' future price movements. The chart of the probability distribution of Immune Therapeutics stock daily returns describes the distribution of returns around its average expected value. We use Immune Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Immune Therapeutics returns is essential to provide solid investment advice for Immune Therapeutics stock.
Mean Return0.09Value At Risk-17.57
Potential Upside14.46Standard Deviation12.11
 Return Density 
      Distribution 
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Immune Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Immune Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Immune Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immune Therapeutics backward and forwards among themselves. Immune Therapeutics' institutional investor refers to the entity that pools money to purchase Immune Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Captrust Financial AdvisorsCommon Shares40.00.0
Mai Capital ManagementCommon Shares12.5 K0.0
Mai Capital ManagementCommon Shares12.5 K0.0
Magnolia Capital Advisors LlcCommon Shares23 K0.0
Mai Capital ManagementCommon Shares12.5 K0.0
Magnolia Capital Advisors LlcCommon Shares23 K0.0
Golden State Wealth Management LlcCommon Shares23 K1000
Note, although Immune Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Immune Therapeutics Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Immune Therapeutics or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Immune Therapeutics stock's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Immune stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over DOW
0.049232
β
Beta against DOW1.07
σ
Overall volatility
12.28
Ir
Information ratio 0.0042

Immune Therapeutics Volatility Alert

Immune Therapeutics is showing large volatility of returns over the selected time horizon. We encourage all investors to investigate this asset further to make sure related market timing strategies are aligned with all the expectations about Immune Therapeutics implied risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Immune Therapeutics' otc stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Immune Therapeutics' otc stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Immune Therapeutics Fundamentals Vs Peers

Comparing Immune Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Immune Therapeutics' direct or indirect competition across all of the common fundamentals between Immune Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Immune Therapeutics or determine the otc stocks which would be an excellent addition to an existing portfolio. Peer analysis of Immune Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Immune Therapeutics by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Immune Therapeutics to competition
FundamentalsImmune TherapeuticsPeer Average
Return On Equity0.0449 %(0.31) %
Current Valuation5.56 M16.62 B
Shares Outstanding481.91 K571.82 M
Shares Owned by Insiders17.25 %10.09 %
Price to Earning0.43 X28.72 X
Price to Book42.25 X9.51 X
Price to Sales152.55 X11.42 X
Revenue48.49 K9.43 B
Gross Profit65.83 K27.38 B
EBITDA(778.5 K)3.9 B
Net Income3.17 M570.98 M
Cash and Equivalents11.66 K2.7 B
Cash per Share0.02 X5.01 X
Total Debt3.07 M5.32 B
Debt to Equity1.97 %48.70 %
Book Value Per Share(22.30) X1.93 K
Cash Flow from Operations(191.5 K)971.22 M
Earnings Per Share6.58 X3.12 X
Number of Employees418.84 K
Beta0.96-0.15
Market Capitalization1.35 M19.03 B
Total Asset23 K29.47 B
Retained Earnings(319.86 M)9.33 B
Working Capital(7.47 M)1.48 B
Current Asset22 K9.34 B
Current Liabilities7.49 M7.9 B
   Immune Therapeutics exotic insider transaction detected [view details]

Immune Therapeutics Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Immune . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
Accumulation Distribution2.87
Daily Balance Of Power(60.00)
Rate Of Daily Change0.79
Day Median Price2.3
Day Typical Price2.3
Market Facilitation Index0.0
Price Action Indicator(0.30)

About Immune Therapeutics Buy or Sell Advice

When is the right time to buy or sell Immune Therapeutics? Buying financial instruments such as Immune OTC Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the stock market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Although Immune Therapeutics investors may find it confusing at the beginning, most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.

Use Investing Ideas to Build Portfolios

In addition to having Immune Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Cars Thematic Idea Now

Cars
Cars Theme
Domestic and international companies involved in manufacturing and serving automobiles and trucks. Cars theme has 30 constituents.
View All  Next Launch Cars
Please see Immune Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note that the Immune Therapeutics information on this page should be used as a complementary analysis to other Immune Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Complementary Tools for Immune OTC Stock analysis

When running Immune Therapeutics price analysis, check to measure Immune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immune Therapeutics is operating at the current time. Most of Immune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Immune Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immune Therapeutics' price. Additionally, you may evaluate how the addition of Immune Therapeutics to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
The market value of Immune Therapeutics is measured differently than its book value, which is the value of Immune that is recorded on the company's balance sheet. Investors also form their own opinion of Immune Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Immune Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immune Therapeutics' market value can be influenced by many factors that don't directly affect Immune Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immune Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Immune Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immune Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.